The Effect of Milnacipran in Patients With Fibromyalgia

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Fibromyalgia

In brief

Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.

Key facts

Study ID

NCT01108731

Run by

Beth Israel Medical Center

People needed

37

Starts

2010-03-01

Expected to finish

2014-01-01

Last updated by the study team

2016-06-30

Who can join

Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Female or male subjects who fulfill the American College of Rheumatology's case definition for Fibromyalgia.
• 18 through 68 years of age

You may not qualify if…

• Pregnant or trying to become pregnant
• Taking any other Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or already taking milnacipran
• Patients who do not indicate their pain levels as less than substantial despite their best care
• History of any psychotic disorder or history of alcoholism or drug abuse within 10 years of intake as determined by psychiatric diagnostic interview
• Presence of current depression as determined by psychiatric diagnostic interview
• Presence of brain lesion on MRI anatomical study

Where it is running

• Pain and Fatigue Study Center - Beth Israel Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.